• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EGEN, Nanotechnology Characterization Lab collaborate in brain cancer research

EGEN, Nanotechnology Characterization Lab collaborate in brain cancer research

September 27, 2011
CenterWatch Staff

EGEN is collaborating with the National Cancer Institute'sNanotechnology Characterization Laboratory in Frederick, Md., to accelerate human clinical testing of a nanotechnology-based gene therapy for brain cancer.

EGEN's candidate gene therapy, which  relies on nanoparticles for effective delivery to the tumor site, is already being evaluated in phase I and II clinical trials in patients with colorectal and ovarian cancers. EGEN is seeking to begin phase I trials against glioblastoma, a brain cancer that is difficult to treat.

The NCI's Nanotechnology Characterization Laboratory, operated under contract by SAIC-Frederick, is part of the NCI Alliance for nanotechnology in cancer, and a partnership between NCI, the National Institute of Standards and Technology, and the FDA. The laboratory evaluates nanoparticles for their physical and chemical properties and for their behavior in laboratory and animal models -- all prerequisite to human testing in medical procedures.

"By working with NCL we are hopeful that we can quickly advance this treatment strategy into additional cancer indications, including brain tumors, where we believe that it may offer significant therapeutic benefit,” said Dr. Jason Fewell, vice president of preclinical research and development for EGEN.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing